Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

The Direct Medical Costs of Colorectal Cancer in Iran; Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan.

Davari M, Maracy MR, Emami MH, Taheri D, Aslani A, Givi M, Massah S.

Int J Prev Med. 2012 Dec;3(12):887-92.

2.

The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan.

Davari M, Yazdanpanah F, Aslani A, Hosseini M, Nazari AR, Mokarian F.

Int J Prev Med. 2013 Jul;4(7):748-54.

3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.
5.

Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer.

Redaelli A, Cranor CW, Okano GJ, Reese PR.

Pharmacoeconomics. 2003;21(17):1213-38. Review.

PMID:
14986736
6.

Hereditary nonpolyposis colorectal cancer and familial colorectal cancer in Central part of Iran, Isfahan.

Nemati A, Rahmatabadi ZK, Fatemi A, Emami MH.

J Res Med Sci. 2012 Jan;17(1):67-73.

7.

Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer.

Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R.

Gastroenterology. 2003 Dec;125(6):1645-50.

PMID:
14724816
8.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
9.

Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.

Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S.

Clin Drug Investig. 2008;28(10):645-55.

PMID:
18783303
10.

Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.

Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR.

Clin Ther. 2004 Apr;26(4):579-89.

PMID:
15189755
11.

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.

Value Health. 2011 Jul-Aug;14(5):647-51. doi: 10.1016/j.jval.2011.01.010. Epub 2011 Jun 22.

12.

Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry.

Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, Fakheri H, Semnani S, Arshi S, Zahedi MJ, Darvish-Moghadam S, Mansour-Ghanaei F, Mosavi A, Malekzadeh R.

Cancer Lett. 2006 Aug 18;240(1):143-7. Epub 2005 Nov 8.

PMID:
16288832
13.

Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysis.

Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J.

BMC Health Serv Res. 2009 Dec 10;9:227. doi: 10.1186/1472-6963-9-227.

14.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

16.

Depression: cost-of-illness studies in the international literature, a review.

Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F.

J Ment Health Policy Econ. 2000 Mar 1;3(1):3-10.

PMID:
11967432
17.

[Cost of colorectal cancer in France in 1999].

Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T.

Gastroenterol Clin Biol. 2003 Jan;27(1):22-7. French.

18.
19.

Cost of disorders of the brain in Europe 2010.

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group..

Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Erratum in: Eur Neuropsychopharmacol. 2012 Mar;22(3):237-8. den Bergh, Peter Van [corrected to Van den Bergh, Peter].

PMID:
21924589
20.

[Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].

Locher C, Auperin A, Boige V, Alzieu L, Pignon JP, Abbas M, Ducreux M.

Gastroenterol Clin Biol. 2001 Aug-Sep;25(8-9):749-54. French.

Supplemental Content

Support Center